glp 1 and 2 agonist GLP-1 receptor agonists in the treatment of type diabetes – state-of-the-art Clinical Focus on GLP-1 Agonists

A Novel CCK-8/GLP-1 hybrid peptide exhibiting prominent insulinotropic, glucose-lowering, and satiety actions with significant therapeutic potential in high-fat-fed mice

Federal law allows states to exclude agents used for weight loss from their Medicaid formularies so covering GLP-1s for obesity is optional, not required

This class has gained popularity and attention in recent years due to its potential to combat obesity

Mediational analysis indicated that weight loss partially mediated the causal effects of GLP-1 RAs on depression and emotional lability, accounting for 18.28% (95% CI: 9.4627.10%, P = 0.038) and 7.65% (95% CI: 5.669.64%, P 0.01 to proxy for GLP-1 RAs exposure

#HLTH2025 #EmployerHealth #GLP1 #FutureOfWork #MakingMoments To view or add a comment, sign in The MercerMarsh Benefits 2026 Health Trends report forecasts continued high medical trend rates globally, driven by inflation and increased utilization, while in the US, total health benefit costs per employee are projected to rise by an average of 6.5%